Aloracetam

Aloracetam

Clinical data
ATC code	none
Legal status
Legal status	US: Not FDA approved; Unscheduled
Identifiers
IUPAC name N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
CAS Number	119610-26-3 Y
PubChem (CID)	178134
ChemSpider	155069 Y
UNII	U0RKZ75D0T Y
ChEMBL	CHEMBL2104637
Chemical and physical data
Formula	C11H16N2O2
Molar mass	208.257 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15) Y Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N Y
(verify)

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.^[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,^[4] but was never marketed.

See also

• Piracetam

References

1. ↑ "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015. 
2. ↑ Charles F. George (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1. 
3. ↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4. 
4. ↑ Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.